Although TRAIL can stimulate the expression of prometastatic molecules like CXCL5/ENA-78 and IL-6 in prostate cancer cells, this effect can be countered using an AKT inhibitor combined with TRAIL (107). Here, CXCL5 is linked to prostate cancer.